This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PETscans per fixed PET site (versus mobile PET) increased 6.7%
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine. “In
mtaschetta-millane Sat, 06/24/2023 - 15:00 June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” ( AWSM-PET ) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging. Louis, Missouri.
Patients with less tau pathology on PETscans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Food and Drug Administration, with a decision expected by the end of 2023. The full report is available here.
milla1cf Wed, 05/31/2023 - 20:52 May 31, 2023 — GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PETscans.
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image. PETscans predict patient response to Pluvicto.
Lancet Oncology 2023; 24(3): e133-e143. Further information available at clinicaltrials.gov - ClinicalTrials.gov Identifier: NCT05629689 - A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PETScans in Patients With Solid Tumour Malignancies 3. link] Thursday, June 15, 2023 - 21:07
Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PETscans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.
Theranostics pairs diagnostic biomarkers that can be visualized on nuclearmedicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. The nuclear radiologist, nuclearmedicine technologist, and radiation safety team are all present to administer an infusion.
mtaschetta-millane Sat, 06/24/2023 - 17:00 June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously indistinguishable brain regions that are known to be involved in Alzheimer’s disease , depressive disorders, visual attention disorders, tinnitus, and other conditions.
Theranostics pairs diagnostic biomarkers that can be visualized on nuclearmedicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. The nuclear radiologist, nuclearmedicine technologist, and radiation safety team are all present to administer an infusion.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content